293 related articles for article (PubMed ID: 1410879)
1. [Role of polyols in the development of diabetic complications. Value of aldose-reductase inhibitors].
Brogard JM; Caro-Sampara F; Blicklé JF
Rev Med Interne; 1992; 13(1):69-79. PubMed ID: 1410879
[TBL] [Abstract][Full Text] [Related]
2. Aldose reductase inhibitors and the complications of diabetes mellitus.
Tomlinson DR
Diabet Med; 1993 Apr; 10(3):214-30. PubMed ID: 8485953
[No Abstract] [Full Text] [Related]
3. Aldose reductase inhibitors and diabetic complications.
Tomlinson DR; Willars GB; Carrington AL
Pharmacol Ther; 1992; 54(2):151-94. PubMed ID: 1438531
[TBL] [Abstract][Full Text] [Related]
4. NIH conference. Aldose reductase and complications of diabetes.
Cogan DG; Kinoshita JH; Kador PF; Robison G; Datilis MB; Cobo LM; Kupfer C
Ann Intern Med; 1984 Jul; 101(1):82-91. PubMed ID: 6203454
[TBL] [Abstract][Full Text] [Related]
5. [Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications].
Hotta N; Sakamoto N
Nihon Rinsho; 1987 Dec; 45(12):3010-27. PubMed ID: 3128677
[No Abstract] [Full Text] [Related]
6. Glutathione redox state is not the link between polyol pathway activity and myo-inositol-related Na+-K+-ATPase defect in experimental diabetic neuropathy.
Carroll PB; Thornton BM; Greene DA
Diabetes; 1986 Nov; 35(11):1282-5. PubMed ID: 3019809
[TBL] [Abstract][Full Text] [Related]
7. Effect of the aldose reductase inhibitor tolrestat on nerve conduction velocity, Na/K ATPase activity, and polyols in red blood cells, sciatic nerve, kidney cortex, and kidney medulla of diabetic rats.
Raccah D; Coste T; Cameron NE; Dufayet D; Vague P; Hohman TC
J Diabetes Complications; 1998; 12(3):154-62. PubMed ID: 9618071
[TBL] [Abstract][Full Text] [Related]
8. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
Kador PF; Kinoshita JH; Sharpless NE
J Med Chem; 1985 Jul; 28(7):841-9. PubMed ID: 3925146
[No Abstract] [Full Text] [Related]
9. [Role of aldose reductase inhibitors in the development of peripheral neuropathy in experimental diabetes].
Kuchmerovskaia TM; Donchenko GV; Klimenko AP; Chichkovskaia GV; Pakirbaeva LV; Kozitskiĭ ZIa; Efimov AS
Ukr Biokhim Zh (1978); 1997; 69(3):77-82. PubMed ID: 9505366
[TBL] [Abstract][Full Text] [Related]
10. Diabetic and galactosaemic cataracts.
Kador PF; Kinoshita JH
Ciba Found Symp; 1984; 106():110-31. PubMed ID: 6439498
[TBL] [Abstract][Full Text] [Related]
11. Aldose reductase in diabetic complications of the eye.
Kinoshita JH; Fukushi S; Kador P; Merola LO
Metabolism; 1979 Apr; 28(4 Suppl 1):462-9. PubMed ID: 45423
[TBL] [Abstract][Full Text] [Related]
12. Does aldose reductase have a role in the development of the ocular complications of diabetes?
Lightman S
Eye (Lond); 1993; 7 ( Pt 2)():238-41. PubMed ID: 7607342
[TBL] [Abstract][Full Text] [Related]
13. Role of aldose reductase in the development of diabetes-associated complications.
Kador PF; Kinoshita JH
Am J Med; 1985 Nov; 79(5A):8-12. PubMed ID: 3934965
[TBL] [Abstract][Full Text] [Related]
14. Aldose reductase, glomerular metabolism, and diabetic nephropathy.
Cohen MP
Metabolism; 1986 Apr; 35(4 Suppl 1):55-9. PubMed ID: 3007926
[TBL] [Abstract][Full Text] [Related]
15. The polyol pathway in retinal microangiopathy.
Robison WG; Kinoshita JH; Kador PF
Drugs; 1986; 32 Suppl 2():19-22. PubMed ID: 3098542
[TBL] [Abstract][Full Text] [Related]
16. Aldose reductase inhibitors and diabetic complications.
Raskin P; Rosenstock J
Am J Med; 1987 Aug; 83(2):298-306. PubMed ID: 3113248
[No Abstract] [Full Text] [Related]
17. [Role of the polyol pathway in the occurrence of degenerative complications of diabetes].
Bosquet F; Grimaldi A
Presse Med; 1986 May; 15(19):879-83. PubMed ID: 3012508
[TBL] [Abstract][Full Text] [Related]
18. Aldose reductase inhibitors and late complications of diabetes.
Benfield P
Drugs; 1986; 32 Suppl 2():43-55. PubMed ID: 3098544
[TBL] [Abstract][Full Text] [Related]
19. Recent studies of aldose reductase enzyme inhibition for diabetic complications.
Suzen S; Buyukbingol E
Curr Med Chem; 2003 Aug; 10(15):1329-52. PubMed ID: 12871133
[TBL] [Abstract][Full Text] [Related]
20. Polyol pathway activity and myo-inositol metabolism. A suggested relationship in the pathogenesis of diabetic neuropathy.
Finegold D; Lattimer SA; Nolle S; Bernstein M; Greene DA
Diabetes; 1983 Nov; 32(11):988-92. PubMed ID: 6416910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
